Terri A. Binder

A Randomized Study of Lenvatinib 18 mg vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer

Marcia S. Brose, Y. Panaseykin, Bhavana Konda et al. · The Journal of Clinical Endocrinology & Metabolism · 2021 · 84 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE₂-receptor E-type 4 (EP4), in patients with advanced cancers

David S. Hong, Aparna R. Parikh, Geoffrey I. Shapiro et al. · Journal for ImmunoTherapy of Cancer · 2020 · 73 citations · Full text

Medicine, Oncology, Pharmacology +17

“New” metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy

Christopher Twelves, Javier Cortés, Peter A. Kaufman et al. · Breast Cancer Research · 2015 · 45 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial

Sumanta K. Pal, Javier Puente, Daniel Yick Chin Heng et al. · European Urology · 2022 · 27 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Exposure–response analysis and simulation of lenvatinib safety and efficacy in patients with radioiodine-refractory differentiated thyroid cancer

Seiichi Hayato, Robert Shumaker, Jim Ferry et al. · Cancer Chemotherapy and Pharmacology · 2018 · 21 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +14